| PDS BIOTECHNOLOGY CORP. |
| USA |
| Gesundheit |
| US70465T1079 / A2PF3F |
| EU6 (Frankfurt) / PDSB (NASDAQ) |
| FRA:EU6, ETR:EU6, EU6:GR, NASDAQ:PDSB |
| - |
| https://www.pdsbiotech.co.. |
|
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing immunotherapies that harness T cells to target cancer. Its current pipeline centers on the Versamune platform, which is designed to stimulate and direct..
>Volltext.. |
| 10.6 Mio. EUR |
| 9.52 Mio. EUR |
| - |
| -23.92 Mio. EUR |
| -29 Mio. EUR |
| -0.55 EUR |
| 3.76 Mio. EUR |
| 4.82 Mio. EUR |
| -14.45 Mio. EUR |
| 0.45 |
| - |
| 5.11% |
| - |
| - |
| - |
| - |
| PDS BIOTECHNOLOGY, PDS BIOTECH |
| 09.09.26 |
|
||||
|
||||
|